Clevidipine in Neurocritical Patients

Hospital de Cruces33 enrolled

Overview

Acute blood pressure elevation is a frequent problem in neurocritical patients. Its effective management is challenging and must avoid significant decreases of blood pressure leading to lower cerebral perfusion pressure worsening ischemia and elevations probably associated with bleeding, rebleeding or hematoma expansion associated with poor prognosis

Retrospective, observational and single-group study for observe effectiveness and safety of clevidipine for perioperative control of hypertension in patients admitted to Post-Operative Intensive Care Unit after thrombectomy for stroke, intracerebral hemorrhage requiring surgical treatment, embolization of aneurysm after subarachnoid hemorrhage, scheduled neurosurgical and neuroradiology procedures.

Study Type

OBSERVATIONAL

Enrollment

Conditions

High Blood Pressure

Interventions

Clevidipine 0.5 MG/ML Intravenous EmulsionDRUG

Effectiveness and safety of clevidipine

Eligibility

Medical Language ↔ Plain English

Inclusion criteria: 1. -Adult patients older than 18 years old admitted to Post-Operative Intensive Care Unit with neurocritical condition requiring surgical or interventional treatment. 2. -Acute High Blood Pressure requiring urgent treatment (SBP ≥160 mmHg or ≥ 20% increase in preoperative values that persists for more than 15 minutes) 3. -Clevidipine used as a first line or after failure of different antihypertensive drugs. Exclusion criteria: 1. -Adults older than 90 years admitted to Post-Operative Intensive Care Unit with neurocritical condition requiring surgical or interventional treatment. 2. -Patients admitted to Post-Operative Intensive Care Unit with neurocritical condition not requiring surgical or interventional treatment.

Locations (1)

Biocruces

Barakaldo, Vizcaya, Spain

Outcomes

Primary Outcomes

Effectiveness of clevidipine

Percentage of patients achieving target systolic blood pressure (SBP)

Time frame: 1 to 6 hour of clevidipine infusion beginning

Secondary Outcomes

Incidence of adverse events related to clevidipine treatment

Tachycardia, atrial fibrillation, hypotension, fever, acute kidney failure, nausea, headache and facial redness.

Time frame: 1 hour after beginning to 24 hours after clevidipine infusion stop

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.